|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZSCAN16-AS1 |
Gene summary for ZSCAN16-AS1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZSCAN16-AS1 | Gene ID | 100129195 |
| Gene name | ZSCAN16 antisense RNA 1 | |
| Gene Alias | ZSCAN16-AS1 | |
| Cytomap | 6p22.1 | |
| Gene Type | ncRNA | GO ID | NA | UniProtAcc | NA |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 100129195 | ZSCAN16-AS1 | S016 | Human | Liver | HCC | 4.51e-16 | 7.41e-01 | 0.2243 |
| 100129195 | ZSCAN16-AS1 | S027 | Human | Liver | HCC | 2.26e-03 | 6.16e-01 | 0.2446 |
| 100129195 | ZSCAN16-AS1 | S028 | Human | Liver | HCC | 3.56e-12 | 7.60e-01 | 0.2503 |
| 100129195 | ZSCAN16-AS1 | S029 | Human | Liver | HCC | 1.99e-06 | 5.55e-01 | 0.2581 |
| 100129195 | ZSCAN16-AS1 | C04 | Human | Oral cavity | OSCC | 1.19e-06 | 5.59e-01 | 0.2633 |
| 100129195 | ZSCAN16-AS1 | C21 | Human | Oral cavity | OSCC | 2.27e-02 | 1.81e-01 | 0.2678 |
| 100129195 | ZSCAN16-AS1 | C30 | Human | Oral cavity | OSCC | 1.34e-14 | 7.91e-01 | 0.3055 |
| 100129195 | ZSCAN16-AS1 | C38 | Human | Oral cavity | OSCC | 4.33e-02 | 5.39e-01 | 0.172 |
| 100129195 | ZSCAN16-AS1 | C46 | Human | Oral cavity | OSCC | 4.85e-06 | 2.54e-01 | 0.1673 |
| 100129195 | ZSCAN16-AS1 | C51 | Human | Oral cavity | OSCC | 5.31e-10 | 4.98e-01 | 0.2674 |
| 100129195 | ZSCAN16-AS1 | C08 | Human | Oral cavity | OSCC | 8.48e-12 | 4.21e-01 | 0.1919 |
| 100129195 | ZSCAN16-AS1 | C09 | Human | Oral cavity | OSCC | 5.79e-09 | 4.34e-01 | 0.1431 |
| 100129195 | ZSCAN16-AS1 | LN22 | Human | Oral cavity | OSCC | 4.53e-04 | 7.15e-01 | 0.1733 |
| 100129195 | ZSCAN16-AS1 | LP15 | Human | Oral cavity | LP | 1.25e-06 | 1.13e+00 | 0.2174 |
| 100129195 | ZSCAN16-AS1 | SYSMH3 | Human | Oral cavity | OSCC | 4.20e-10 | 4.69e-01 | 0.2442 |
| 100129195 | ZSCAN16-AS1 | SYSMH5 | Human | Oral cavity | OSCC | 2.10e-04 | 3.26e-01 | 0.0647 |
| 100129195 | ZSCAN16-AS1 | SYSMH6 | Human | Oral cavity | OSCC | 1.18e-03 | 1.82e-01 | 0.1275 |
| 100129195 | ZSCAN16-AS1 | male-WTA | Human | Thyroid | PTC | 4.53e-20 | 3.72e-02 | 0.1037 |
| 100129195 | ZSCAN16-AS1 | PTC01 | Human | Thyroid | PTC | 1.07e-14 | 1.18e-02 | 0.1899 |
| 100129195 | ZSCAN16-AS1 | PTC04 | Human | Thyroid | PTC | 1.05e-09 | -4.41e-04 | 0.1927 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |